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Abstract ErbB receptor activation is a complex process and is
dependent upon the type and number of receptors expressed on a
given cell. Previous studies with defined combinations of ErbB
receptors expressed in mammalian cells have helped elucidate
specific biological responses for many of the recognized gene
products that serve as ligands for these receptors. However, no
study has examined the binding of these ligands in a defined
experimental system. To address this issue, the relative binding
affinities of the egf domains of eleven ErbB ligands were
measured on six ErbB receptor combinations using a soluble
receptor-ligand binding format. The ErbB2/4 heterodimer was
shown to bind all ligands tested with moderate to very high
affinity. In contrast, ErbB3 showed much more restrictive ligand
binding specificity and measurable binding was observed only
with heregulin, neuregulin2L, epiregulin and the synthetic here-
gulin/egf chimera, biregulin. These studies also revealed that
ErbB2 preferentially enhances ligand binding to ErbB3 or ErbB4
and to a lesser degree to ErbB1.
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1. Introduction
Members of the EGF ligand family bind directly to three of
four known ErbB receptors in mammals [1]. Presently, there
are 11 distinct human egf domains, encoded by nine di¡erent
genes [1,2]. Although numerous ligands have been identi¢ed,
in many cases receptor speci¢cities and a⁄nities have not been
reported. One reason for the lack of receptor-ligand character-
ization, may be due to the complexity of the relationship
between ligand binding and a biological response. Conse-
quently, numerous types of assays have been used to analyze
ligand function. In an e¡ort to address this issue the binding
a⁄nities of epidermal growth factor (egf)-like ligands were
measured in a simpli¢ed system utilizing ErbB receptor ex-
tracellular domains fused to immunoglobulins (ErbB-IgGs).
Previous studies have shown that heregulinL (HRGL) binds
to soluble heterodimeric-IgGs containing ErbB2 with ErbB3
or ErbB4 (designated ErbB2/3-IgG or ErbB2/4-IgG) with ap-
proximately 100-fold higher a⁄nity than the corresponding
homodimers of ErbB3-IgG or ErbB4-IgG [3]. A similar shift
in binding a⁄nities is also observed when the receptors are
expressed in mammalian cells [4,5]. Here, we report the appar-
ent binding a⁄nities of the egf domains of 10 naturally occur-
ring ligands and the chimeric molecule, biregulin (BiR) [6].
These studies demonstrate that ErbB2 universally increases
ligand a⁄nity when complexed with either ErbB3 or ErbB4.
In addition, some ligands appear to allosterically a¡ect the
binding of a second ligand to particular receptor complexes.
2. Materials and methods
2.1. Reagents
The egf domains of HRGL (177^244) [4,7] and HRGK (177^239) [8]
were expressed in bacteria and puri¢ed as described previously.
HRGL was radioiodinated as described previously [4] and is referred
to as [125I]HRGL in this paper. Preparation of ErbB-IgGs was de-
scribed in Fitzpatrick et al. [3]. Human recombinant forms of beta-
cellulin (BTC), heparin binding epidermal growth factor (HB-EGF)
and transforming growth factor K (TGFK) were purchased from R
and D Systems (Minneapolis, MN). Human recombinant EGF was
purchased from Calbiochem (San Diego, CA). [125I]EGF, human re-
combinant form, was obtained from Amersham Life Sciences (Arling-
ton Heights, IL).
2.2. Thioredoxin-ligand preparations
Trx-HRGL generation was described previously [9]. Trx-HRGL
contains amino acid residues 146^244 of HRGL fused to the carboxyl
terminus of thioredoxin. Neuregulin-3 (NRG3) was generated by PCR
using oligonucleotides containing a KpnI restriction site at the 5P end
and a SalI site at the 3Pend. This fragment was subcloned into the trx-
vector [9].
The egf domains of neuregulin-2K (NRG2K), neuregulin-2L
(NRG2L) and epiregulin (EPR) were generated synthetically by
PCR using six overlapping oligonucleotides (36^49 bases in length).
The epiregulin used in these experiments corresponded to the mouse
form of the protein [10]. At the time the experiments were initiated the
human gene had not been cloned [11]. The oligonucleotides for epi-
regulin and NRG2K [12^14] were designed from published DNA se-
quences. Oligonucleotides corresponding to the C-terminal region of
NRG2L were designed based on the amino acid sequence. Adjacent
pairs of oligonucleotides were utilized as templates in standard PCR
reaction mixes, utilizing PFU enzyme (Perkin-Elmer). PCR (5 cycles;
1 min at 94‡C, 1 min at 58‡C and 2 min at 72‡C) was conducted in a
9600 Perkin Elmer PCR machine. Aliquots (1/10 of each the above
reactions) containing the next most adjacent oligonucleotides, were
combined in a new reaction, containing dNTPs and PFU for ¢ve
more rounds of PCR. Lastly, 1/20 of each of the above two reactions
were combined with 1 Wl of each oligonucleotide corresponding to the
5P and 3P ends of the desired ¢nal molecule for 25 additional PCR
cycles. The 5P oligonucleotides contained a KpnI site and the 3P oli-
gonucleotides contained a stop codon followed by a SalI site for
cloning into the trx vector. The egf-domain boundaries include 4^5
amino acids preceding the ¢rst cysteine and eight residues past the
sixth cysteine. Expression and puri¢cation of trx-egf domains was
performed as described previously [9]. Each protein was quanti¢ed
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by amino acid analysis and its mass con¢rmed by mass spectrometry.
Refolding was analyzed by analytical reverse phase chromatography.
2.3. Ligand binding assays on ErbB-IgGs
Binding assays were done as described previously for ErbB3-IgG
assays [3,9]. Brie£y, 96 well microtiter plates were coated with 2.5 ng/
well heterodimeric-IgGs or 25 ng/well homodimeric-IgGs. The con-
centration of radiolabeled ligand added was between 50^100 pM.
Competitive ligands were added up to a ¢nal concentration of 5 WM.
Assays were conducted over at least 2.5 orders of magnitude of con-
centration, using 8^12 di¡erent concentrations (3-fold dilutions). Each
data point is the mean of triplicate measurements. IC50 values were
calculated from a four parameter ¢t calculation of the curve. It is
worth noting that the apparent a⁄nity of trx-HRGL is lower than
that measured for HRGL177ÿ244. Apparent binding constants less than
200 pM are estimates and are less precise due to the amount of radio-
labeled tracer needed in the assay.
2.4. Cell binding assays
Assays on ErbB4 K562 cells were carried out as described in Jones
et al. [9], except that 200 000 cells were used per well. Cells were
treated with 10 ng/ml of phorbol 12-myristate 13-acetate for 24 h
preceding assay initiation.
3. Results
3.1. Heregulin
Although HRGK and HRGL isoforms are identical in the
egf domain sequence up to the ¢fth cysteine (Fig. 1) and both
directly bind ErbB3 and ErbB4, their binding a⁄nities are
quite di¡erent. Using competitive binding analysis with
[125I]HRGL, HRGK binding was 100-fold weaker than
HRGL for the ErbB3 and ErbB4 homodimers. This observa-
tion is in general agreement with that reported previously with
ErbB3 transfected 32D cells [15] and with the breast cancer
cell line, SK-BR-3 [16]. The IC50 for both HRG isoforms was
decreased signi¢cantly in heterodimers containing ErbB2 (Ta-
ble 1) [3,4]. Biological di¡erences between HRGK and HRGL
have been noted previously [15,17^19], and are likely due to
di¡erential a⁄nity. For instance, Raabe et al. [20], found that
HRGL was a potent mitogen for Schwann cells, whereas
HRGK was not. Since Schwann cells mitogenesis is primarily
mediated through ErbB2/ErbB3 complexes [21], the decreased
binding a⁄nity of HRGK for this neuregulin receptor likely
accounts for its inability to function as a Schwann cell mito-
gen at the concentrations tested. The extent to which HRGK
has much weaker a⁄nity for homodimeric receptors was not
previously determined [6,17,18].
3.2. Neuregulin-2
The two NRG2 isoforms, like HRG, di¡er in sequence only
past the ¢fth cysteine (Fig. 1). We found that trx-NRG2K
bound heterodimeric ErbB2/4-IgG, but no displacement of
[125I]HRGL was measured for the other ErbB3- and ErbB4-
IgGs. Trx-NRG2L was able to displace [125I]HRGL from
ErbB2/3-, ErbB4- and ErbB2/4-IgGs but had no measurable
a⁄nity for ErbB3-IgG. Thus NRG2L appears to bind ErbB4
preferentially compared to ErbB3. We saw no evidence for
interaction of either NRG2 isoform with EGFR, nor could
we compete [125I]EGF from ErbB1-containing IgGs (Table 1).
Previously, both NRG2 isoforms were shown to activate all
the ErbB receptors in a variety of cell types [12^14] as deter-
mined by receptor tyrosine phosphorylation analysis. The rel-
atively weak binding of NRG2 for ErbB3 may account for its
reported lack of acetylcholine receptor inducing activity
(ARIA) [14].
3.3. Neuregulin-3
In agreement with earlier studies, trx-NRG3 demonstrated
binding only to ErbB4- and ErbB2/4-IgGs [2]. In our system,
the a⁄nity of trx-NRG3 for ErbB4 was characterized by an
increase in counts bound at the lowest concentrations fol-
lowed by displacement with an IC50 of V2.4 WM. The e¡ect
of binding enhancement was maximal at about 100 nM trx-
NRG3 on both ErbB4-IgG (Table 1) and ErbB4 K562 cells
(Fig. 2A). When competitive HRGL binding assays were per-
formed in the presence of 100 nM trx-NRG3, Scatchard anal-
ysis revealed a second, high a⁄nity site. In contrast, Scatchard
plots of trx-NRG3 binding to the ErbB2/4 heterodimeric IgGs
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Fig. 1. Sequence alignment of egf domains of ligands used in this
study. Conserved residues are shown in bold. Shaded residues are
known to be critical for ErbB3 or EGFR binding.
Table 1
Summary of relative IC50 for various ligands to ErbB-IgG constructs
Ligands I-C50, nM
125I[EGF] 125I[HRG]
ErbB1 ErbB1/2 ErbB3 ErbB2/3 ErbB4 rbB2/4
HRGK NMBa NMB 550 48 510 7.4
HRGL NMB NMB 5.4 0.2 5.1 0.1
trx-HRGL NMB NMB 28 0.7 18 0.3
trx-NRG2K NMB NMB NMB NMB NMB 450
trx-NRG2L NMB NMB NMB 460 56 0.4
trx-NRG3K NMB NMB NMB NMB 2400 200
trx-EPR K 2800 2400 NMB 230 NMB 110
BTC K 1.4 1.7 NMB NMB 3.6 0.2
HB-EGF K 7.1 3.4 NMB NMB NMB 310
EGF K 1.9 1.2 NMB NMB NMB 49
TGF K 9.2 6.4 NMB NMB NMB 340
trx-BiR 2.7 0.7 1100 32 23 0.9
aNo measurable binding or calculated IC50 is greater than 5 WM.
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yielded a single binding site (data not shown). To date, we
have not been able to successfully radiolabel NRG3 and
maintain binding to ErbB4. We speculate that NRG3 and
HRGL have overlapping but di¡erent receptor binding sites,
which enables NRG3 to a¡ect the binding of HRGL. The
higher apparent a⁄nity reported previously is likely a conse-
quence of ligand avidity, since the NRG3 was a dimeric Fc
fusion protein [2].
3.4. Epiregulin
EPR has been reported to be a ligand for both EGFR and
ErbB4 [11,22,23], however the a⁄nity of EPR for these recep-
tors has not been examined. Komurasaki et al. [11], using
chemical crosslinking, concluded that EPR bound directly to
EGFR and ErbB4. They also reported that the magnitude of
ErbB4 tyrosine phosphorylation upon treatment with EPR
was greater than that observed with EGFR. In contrast, Riese
et al. [23] reported that four times more ligand was required
for ErbB4-receptor autophosphorylation compared to EGFR
autophosphorylation. EPR interaction with these receptors is
further complicated due to the ability of ErbB2 to increase
sensitivity of ErbB4 to EPR and from potential interactions
with cell surface proteoglycans [23]. In our study, trx-EPR
had low a⁄nity for EGFR and ErbB4. The IC50s for
[125I]EGF displacement from ErbB1- and ErbB1/2-IgGs
were V2.5 WM, while the IC50s for [125I]HRGL displacement
from ErbB4 (both IgGs and in cells) were greater than 5 WM
(Table 1, Fig. 2B). As observed with other ligands, the a⁄nity
was increased when ErbB2 was present with ErbB4 and
ErbB3 (Table 1). Trx-EPR was also able to displace [125I]EPR
from the IgGs with very similar IC50s compared to its dis-
placement of [125I]EGF and [125I]HRGL, suggesting utilization
of similar receptor binding sites (data not shown).
3.5. Betacellulin
Using competition binding with [125I]HRGL and [125I]EGF,
betacellulin was found to bind to ErbB4-, ErbB2/4- and
ErbB1-IgGs with relatively high a⁄nities (3.6 nM, 0.2 nM
and 1.4 nM, respectively). BTC is unique among the EGF
family in that it has high a⁄nity for both EGFR and
ErbB4 [24,25]. BTC bound with higher a⁄nity than trx-
HRGL to both ErbB4 (Fig. 2A) and ErbB2/4 K562 cells. In
agreement with previous studies [25], we could not accurately
measure an IC50 for BTC binding to ErbB3-IgG, although
there was slight displacement of [125I]HRGL from ErbB2/3-
IgG at concentrations (s 1 WM). This result is consistent with
three recent reports demonstrating BTC binding to ErbB2/3
complexes in cells [26^28].
3.6. Heparin-binding epidermal growth factor
HB-EGF has been shown to bind EGFR and ErbB4 recep-
tors when they are singly transfected in NIH3T3 cells [29]. In
agreement with this observation, we found that HB-EGF was
able to displace [125I]EGF from all ErbB1-containing IgGs
with IC50s in the nanomolar range (Table 1). However, HB-
EGF was unable to displace [125I]HRGL binding from ErbB3-
, ErbB2/3- or ErbB4-IgGs (Table 1). The IC50 measured on
ErbB2/4-IgG was V300 nM. Cell surface heparin, heparin
sulfate and sulfate glycosaminoglycans may alter binding of
HB-EGF in either a stimulatory or inhibitory way, depending
upon the cell type [30^32]. The addition of heparin (0.5 Wg/ml)
had no e¡ect on HB-EGF binding to the ErbB-IgG constructs
(data not shown). The activation of ErbB4 phosphorylation
by HB-EGF was reported for some natural cell lines and
transfected NIH3T3 cells, but not in ErbB4 transfected
BaF3 cells, which are known to lack some proteoglycans
[33]. These results suggest that HB-EGF binding to ErbB4
and EGF may require di¡erent proteoglycan components.
Alternatively, HB-EGF may use the same binding site on
EGFR as does EGF, but may not use the HRGL binding
site on ErbB4.
3.7. EGF and TGFK
It has become increasingly clear from recent reports
[26,34,35] that EGF and TGFK exhibit low a⁄nity binding
for ErbB3 and ErbB4, which is enhanced by ErbB2. At high
concentrations (s 5 WM) slight displacement of [125I]HRGL
by EGF from ErbB2/3-, ErbB3- or ErbB4-IgGs was observed.
TGFK behaved similarly to EGF with regard to receptor spe-
ci¢city, but exhibited even lower a⁄nity for ErbB3- or ErbB4-
IgGs. The estimated IC50 values for displacement of
[125I]HRGL by either ligand from ErbB4 K562 cells was in
the 5^20 WM range (Fig. 2B).
3.8. Biregulin
Biregulin (BiR) is a chimeric the egf domain, in which
the amino terminal residues (NSDSE) of EGF, have been
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Fig. 2. [125I]HRGL displacement from K562 cells expressing ErbB4
receptors. A: E¡ect of trx-NRG2L and trx-NRG3 on [125I]HRGL
binding. B: Ability of EGF, TGFK and trx-EPR to displace
[125I]HRGL at high concentrations.
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replaced with the corresponding residues of HRG (SHLVK)
[6]. Trx-BiR had measurable a⁄nity for three receptors,
ErbB3-, ErbB4- and ErbB1-IgGs (1 WM, 23 nM and 2.7
nM, respectively). The a⁄nity increased to 32 nM for
ErbB2/3-IgG and 0.9 nM for ErbB2/4-IgG. Our previous
studies have shown that His178 and Leu179 of HRGL are crit-
ical for binding to ErbB3 [9]. In biregulin, this sequence may
also form a L strand that can pack with the two strands of the
major L sheet, converting EGF into a more HRG-like mole-
cule.
4. Discussion
4.1. Summary of ligand binding interactions to ErbB receptors
A summary of ligand binding analysis with six soluble ho-
modimer or heterodimer receptor combinations is shown in
Table 2. We classi¢ed these receptor-ligand interactions into
¢ve di¡erent categories ranging from very high a⁄nity (6 1
nM) to no measurable binding (s 5 WM). The speci¢city of
ligands for these soluble homodimeric receptors di¡ers some-
what from that reported for receptor speci¢city derived from
cell transfection studies. Notably, we found that NRG2 binds
with moderate a⁄nity to the heterodimeric ErbB2/3-IgG, but
has no measurable a⁄nity for ErbB3-IgG. Similarly, NRG3,
EPR, HB-EGF, and TGFK have no measurable a⁄nity for
ErbB4-IgG but moderate a⁄nity for ErbB2/4-IgG. The non-
naturally occurring ligand, BiR, binds ErbB4-IgG signi¢cantly
tighter than it binds ErbB3-IgG.
4.2. ErbB2 increases a⁄nity in complexes containing
heterodimeric receptors
Ligands displaced [125I]HRGL better from ErbB receptor-
IgGs containing ErbB2 plus ErbB3 or ErbB4 compared to
ErbB3 or ErbB4 alone (Tables 1 and 2). ErbB2 does not
appear to recruit new speci¢city, but rather increases a⁄nity.
In our study, ErbB2 only slightly increased a⁄nity for ligands
binding EGFR (Table 1). Although it has been shown previ-
ously that ErbB2 increases a⁄nity for HRGL [3^5], the gen-
erality of this a⁄nity enhancement has not been appreciated
for all known ligands that bind to ErbB3 and ErbB4 hetero-
dimers. Since ErbB2 is the preferred partner for heterodime-
rization and has enhanced signaling potential [5,36], the in-
creased level of receptor phosphorylation in complexes
containing ErbB2 may be due in part to a decreased o¡ rate
[5]. It is not clear how ErbB2 is involved in generating the
high a⁄nity complex. ErbB2 may alter the conformation of
the second primary ligand binding receptor, resulting in a shift
of the existing binding interaction from lower to higher a⁄n-
ity. This may or may not involve direct contact between
ErbB2 and the ligand.
4.3. Structure/function correlations
There are nine absolutely conserved residues, including the
six cysteines, within the egf domains shown in Fig. 1. Se-
quence identity to HRGL ranges from 79% for HRGK to
24% for EGF and mEPR. Despite primary sequence diversity,
the tertiary structures of EGF, TGFK, HRGK, and HB-EGF
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Table 2
Classi¢cation of of ligands according to their relative a⁄nities toward ErbB-IgGs
Very high a⁄nity
(6 1 nM)
High a⁄nity
(1^100 nM)
Moderate a⁄nity
(100^1000 nM)
Low a⁄nity
(s 1000 nM)
No measurable
binding
ErbB4 BTC HRGK NRG3 EGF
HRGL TGFK
BiR HB-EGF
NRG2L EPR
NRG2K
ErbB2/4 BTC HRGK NRG3
HRGL EGF EPR
BiR HB-EGF
NRG2L TGFK
NRG2K
ErbB3 HRGL HRGK BiR EGF
TGFK
HB-EGF
EPR
NRG2K
NRG2L
NRG3
BTC
ErbB2/3 HRGL HRGK NRG2L EGF
BiR EPR TGFK
HB-EGF
NRG2K
BTC
ErbB1 TGFK EPR HRGK
EGF HRGL
BTC NRG2K
HB-EGF NRG2L
BiR NRG3
ErbB1/2 TGFK EPR HRGK
EGF HRGL
BTC NRG2K
HB-EGF NRG2L
BiR NRG3
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the four structures solved to date, are very similar [8,37^39].
The relative orientation of the two L sheet domains is virtually
identical and residues that a¡ect binding to ErbB receptors
have been identi¢ed in numerous mutagenesis studies of
HRG, TGFK and EGF. Many of the same regions also ap-
pear to be required for the binding of other egf domains to
ErbB receptors. For instance, the shorter omega loop found in
TGFK and EGF is present in all ligands binding to EGFR,
while the size of the loop is not critical for ErbB3 or ErbB4
binding [6,40^42]. Likewise, all ligands that bind to EGFR
contain a leucine at the ¢fth position past the sixth cysteine,
which has been shown to be important EGF and TGFK bind-
ing [43]. Ligands that bind to ErbB3-IgG all contain the se-
quence SHLVK at the amino terminus. These residues may
contribute to the formation of the ¢rst L strand in HRGK,
which is less structured in EGF and TGFK. This strand is
critical for the formation of a 3 stranded L sheet, unique to
HRG. Thus, ErbB3 receptor speci¢city may be broadly de-
¢ned by the sheet structure rather than the primary sequence.
In contrast, ErbB4 is more promiscuous than ErbB3 and in
the presence of ErbB2 is able to bind all ligands tested. It is
di⁄cult to identify speci¢c features required for ErbB4 bind-
ing. Since BTC binds both EGFR and ErbB4 with relatively
high a⁄nity, a high resolution solution structure of BTC may
provide insight as to structural elements involved in receptor
speci¢city.
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